pharmaceutically-acceptable carrier, wherein the respiratory disease is a lung infection, a helminthic infection, pulmonary arterial hypertension, sarcoidosis, lymphangioleiomyomatosis, bronchiectasis, or an infiltrative pulmonary disease.

In yet another aspect, the invention provides a method of treating a respiratory disease in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising compound **1** or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier, wherein the respiratory disease is drug-induced pneumonitis, fungal induced pneumonitis, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, eosinophilic granulomatosis with polyangiitis, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, hypereosinophilic syndrome, Löffler syndrome, bronchiolitis obliterans organizing pneumonia, or immune-checkpoint-inhibitor induced pneumonitis.

In a further aspect, there is provided a use of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of an ocular disease in a mammal, wherein the ocular disease is uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, or atopic keratoconjunctivitis.

In another aspect, there is provided a use of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease in a mammal, wherein the respiratory disease is a lung infection, a helminthic infection, pulmonary arterial hypertension, sarcoidosis, lymphangioleiomyomatosis, bronchiectasis, or an infiltrative pulmonary disease.


In yet another aspect, there is provided a use of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease in a mammal, wherein the respiratory disease is drug-induced pneumonitis, fungal induced pneumonitis, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, eosinophilic granulomatosis with polyangiitis, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia,

hypereosinophilic syndrome, Löffler syndrome, bronchiolitis obliterans organizing pneumonia, or immune-checkpoint-inhibitor induced pneumonitis.

DETAILED DESCRIPTION OF THE INVENTION

Chemical structures are named herein according to IUPAC conventions as implemented in ChemDraw software (PerkinElmer, Inc., Cambridge, MA).

Furthermore, the imidazo portion of the tetrahydroimidazopyridine moiety in the structure of the present compound exists in tautomeric forms. The compound could equivalently be represented as



According to the IUPAC convention, these representations give rise to different numbering of the atoms of the imidazopyridine portion. Accordingly this structure is designated 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-**3***H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol. It will be understood that although structures are shown, or named, in a particular form, the invention also includes the tautomer thereof.

WHAT IS CLAIMED IS:

1. Use of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of an ocular disease in a mammal, wherein the ocular disease is uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, or atopic keratoconjunctivitis.

2. The use of claim 1, wherein the ocular disease is uveitis.

3. The use of claim 2, wherein the ocular disease is diabetic macular edema.

4. The use of claim 1, wherein the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol is administered by injection.

5. Use of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease in a mammal, wherein the respiratory disease is a lung infection, a helminthic infection, pulmonary arterial hypertension, sarcoidosis, lymphangioleiomyomatosis, bronchiectasis, or an infiltrative pulmonary disease.

6. The use of claim 5, wherein the medicament is suitable to be administered by inhalation.

7. The use of claim 6, wherein the medicament is suitable to be administered with a nebulizer inhaler.

8. The use of claim 6, wherein the medicament is suitable to be administered with a dry powder inhaler.

9. The use of claim 5, wherein the respiratory disease is sarcoidosis.

10. Use of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-c]pyridin-2-yl)-1*H*-indazol-6-yl)phenol, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease in a mammal, wherein the respiratory disease is drug-induced pneumonitis, fungal induced pneumonitis, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, eosinophilic granulomatosis with polyangiitis, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, hypereosinophilic syndrome, Löffler syndrome, bronchiolitis obliterans organizing pneumonia, or immune-checkpoint-inhibitor induced pneumonitis.

11. The use of claim 10, wherein the medicament is suitable to be administered by inhalation.

12. The use of claim 11, wherein the medicament is suitable to be administered with a nebulizer inhaler.

13. The use of claim 12, wherein the medicament is suitable to be administered with a dry powder inhaler.

14. The use of claim 10, wherein the respiratory disease is hypersensitivity pneumonitis.

15. The use of claim 10, wherein the respiratory disease is bronchiolitis obliterans organizing pneumonia.

16. The use of claim 10, wherein the respiratory disease is immune-checkpoint-inhibitor induced pneumonitis.

17. The use of claim 10, wherein the respiratory disease is drug-induced pneumonitis.

18. The use of claim 10, wherein the respiratory disease is eosinophilic granulomatosis with polyangiitis

19. The use of claim 10, wherein the respiratory disease is idiopathic acute eosinophilic pneumonia or idiopathic chronic eosinophilic pneumonia.

20. The use of claim 10, wherein the respiratory disease is fungal induced pneumonitis, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, hypereosinophilic syndrome, or Löffler syndrome.